Patents by Inventor Roger ESTRADA TEJEDOR

Roger ESTRADA TEJEDOR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITOR OF MAP KINASE INTERACTING SERINE/THREONINE KINASE 1 (MNK1) AND MAP KINASE INTERACTING SERINE/THREONINE KINASE 2 (MNK2), CANCER THERAPY AND THERAPEUTIC COMBINATIONS
    Publication number: 20220257571
    Abstract: The present invention describes 4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine (EB1), or a pharmaceutically acceptable salt thereof, as a selective MNK inhibitor for use in the treatment of cancers of an hormone-dependent organs, including triple-negative breast cancer, prostate cancer and other referable cancers with p-eIF4E overexpression due to increased MNK activity. The invention also includes particular therapeutic combinations including the 4,6-diphenyl-1H-pyrazolo[3,4-b]pyridin-3-amine.
    Type: Application
    Filed: July 9, 2020
    Publication date: August 18, 2022
    Inventors: Santiago RAMON Y CAJAL AGÜERAS, Stefan HÜMMER, Josep CASTELLVI VIVES, Elena MARTINEZ SÁEZ, José Ignacio BORRELL BILBAO, Jordi TEIXIDÓ CLOSA, Roger ESTRADA TEJEDOR, Elisabeth BOU PETIT, Vicente PEG CAMARA, Pedro Jesus GUIJARRO CARRILLO, Anna SANTAMARIA MARGALEF, Joan MOROTE ROBLES, Leticia SUAREZ CABRERA
  • Compounds for the treatment of myotonic dystrophy
    Patent number: 10226467
    Abstract: The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 12, 2019
    Assignees: Universitat de Valencia, Institut Quimic de Sarria Cets Fundacio Privada, Institut Univ. de Ciencia I Tecnologia, S.A.
    Inventors: Ruben Artero Allepuz, Josep Castells Boliart, José Ignacio Borrell Bilbao, Beatriz Llamusi Troísi, Ariadna Bargiela Schönbrunn, Piotr Konieczny, Marta Pascual Gilabert, Jordi Teixidó Closa, Roger Estrada Tejedor, Alejandro López González
  • COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY
    Publication number: 20170312285
    Abstract: The present invention relates to a compound of formula (I), provided that this compound is not caffeine, for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising the compound of formula (I). The present invention further relates to new compounds which are dimers of compounds of formula (I).
    Type: Application
    Filed: November 13, 2015
    Publication date: November 2, 2017
    Inventors: Ruben ARTERO ALLEPUZ, Josep CASTELLS BOLIART, José Ignacio BORRELL BILBAO, Beatriz LLAMUSI TROÍSI, Ariadna BARGIELA SCHÖNBRUNN, Piotr KONIECZNY, Marta PASCUAL GILABERT, Jordi TEIXIDÓ CLOSA, Roger ESTRADA TEJEDOR, Alejandro LÓPEZ GONZÁLEZ
  • CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2
    Publication number: 20170304309
    Abstract: The present invention relates to caffeine for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising caffeine for use in the treatment of myotonic dystrophy type 1 and type 2.
    Type: Application
    Filed: November 13, 2015
    Publication date: October 26, 2017
    Inventors: Ruben ARTERO ALLEPUZ, Josep CASTELLS BOLIART, José Ignacio BORRELL BILBAO, Beatriz LLAMUSI TROÍSI, Ariadna BARGIELA SCHÖNBRUNN, Piotr KONIECZNY, Marta PASCUAL GILABERT, Jordi TEIXIDÓ CLOSA, Roger ESTRADA TEJEDOR, Alejandro LÓPEZ GONZÁLEZ